List view / Grid view
The approval of ALPROLIX is first significant advance in hemophilia…
21 March 2014 | By Biogen Idec
The approval of ALPROLIX is first significant advance in hemophilia B treatment in more than 17 years ...
Agreement to enhance R&D capabilities and pipeline aimed at creating…
5 March 2014 | By Biogen Idec
Agreement to enhance R&D capabilities and pipeline aimed at creating new therapies to suppress Alzheimer’s disease progression...
Stelios Papadopoulos to become Chairman of the Board...
17 February 2014 | By Biogen Idec
Stelios Papadopoulos to become Chairman of the Board...
Biogen Idec to begin launching TECFIDERA in initial EU Countries…
3 February 2014 | By Biogen Idec
Biogen Idec to begin launching TECFIDERA in initial EU Countries in the coming weeks...
Biogen Idec has completed its purchase of Elan Corporation’s interest…
2 April 2013 | By Biogen Idec
Biogen Idec has completed its purchase of Elan Corporation’s interest in TYSABRI® (natalizumab)...
The U.S. FDA has approved TECFIDERA™...
27 March 2013 | By Biogen Idec
The U.S. FDA has approved TECFIDERA™...
European Commission decision anticipated in second quarter of 2013...
22 March 2013 | By GCI Health
European Commission decision anticipated in second quarter of 2013...
Biogen Idec has agreed to purchase Elan’s interest in TYSABRI...
6 February 2013 | By Biogen Idec
Biogen Idec has agreed to purchase Elan’s interest in TYSABRI...
Biogen Idec dedicated a new facility in Research Triangle Park…
29 November 2012 | By Biogen Idec
Biogen Idec dedicated a new facility in Research Triangle Park (RTP), consolidating its 300-person Patient Services operation with the existing RTP campus...
Kenneth DiPietro named Executive Vice President, Human Resources...
30 January 2012 | By Biogen Idec
Kenneth DiPietro named Executive Vice President, Human Resources...
Biogen Idec and Isis Pharmaceuticals, Inc. have entered into an…
4 January 2012 | By Biogen Idec
Biogen Idec and Isis Pharmaceuticals, Inc. have entered into an exclusive, worldwide option and collaboration agreement...
Samsung and Biogen Idec announced that they have entered into…
5 December 2011 | By Biogen Idec
Samsung and Biogen Idec announced that they have entered into an agreement to invest $300 million to establish a joint venture to develop, manufacture and market biosimilars...
